Dampening of the renin-angiotensin signaling cascade (RAS) has proven invaluable in the treatment of cardiovascular disease. Drugs that inhibit the M2 family dicarboxymetallopeptidase angiotensin-converting enzyme (ACE, EC 3.4.15.1) or the A1 family aspartic protease renin (EC 3.4.23.15), as well as those that antagonize the 7-transmembrane G protein-coupled angiotensin receptor II (AT~2~), improve hypertension. Dual ACE and M13 metalloprotease neutral endopeptidase (neprilysin, NEP, EC 3.4.24.11) inhibition has also been explored for the treatment of high blood pressure. Recently, a new member of the RAS, the M2 family monocarboxymetallopeptidase angiotensin-converting enzyme 2 (ACE2), was identified.[@bib1], [@bib2] It is a membrane-associated and secreted metalloprotease, expressed in heart, kidney, testes, intestine, and lung, with highest homology to ACE. ACE2 has been implicated in cardiovascular disease, kidney disease, obesity, and lung disease.[@bib3], [@bib4], [@bib5]

Angiotensin I and the AT~1~ & AT~2~ receptor agonist angiotensin II are substrates for ACE2, which converts them into angiotensin (1-9) and the *mas* receptor agonist angiotensin (1-7), respectively, revealing a role for ACE2 in RAS regulation. Moreover, ACE2 (−/−) mice studies have revealed roles for this protease in cardiac contractility,[@bib6] angiotensin II-induced hypertension,[@bib7] and heart failure.[@bib8] Furthermore, male ACE2 (−/Y) mice, but not female ACE2 (−/−) mice, also develop glomerulosclerosis of the kidneys,[@bib9] but ACE2's exact role in the renin-angiotensin system (RAS) still needs to be clarified. In addition, ACE2 (−/−) mice are resistant to weight gain on a high fat diet.[@bib10] Finally, ACE2 is the primary receptor for the severe acute respiratory syndrome (SARS) corona virus's entry into cells.[@bib11] ACE2 (−/−) mice resist SARS corona virus infection.[@bib12] Because of limited space, the authors refer the interested reader to a recent review by Hamming et al. for a more comprehensive summary of the physiology and pathology of ACE2.[@bib13]

With the many putative roles of ACE2, small molecule modulators of this enzyme's activity could be utilized to help further define the physiological functions of this enzyme. Although small molecule inducers of proteases are difficult to discover, ACE2 activators could provide further insight into the functions of ACE2 and the substrates it processes. Similarly, inhibitors could also shed more light on the roles of ACE2 and the proteins/peptides it activates/degrades.

Efforts to discover ACE2 inhibitors have recently been disclosed. Millennium Pharmaceutical researchers reported the discovery of a reversible, subnanomolar ACE2 inhibitor MLN-4760 (IC~50~  = 0.44 nM), derived from a micromolar lead.[@bib14] In addition, Dyax researchers identified micromolar peptide inhibitors of ACE2 using a phage display library approach, including the 29 amino acid cyclic peptide DX600 (IC~50~  = 10 nM).[@bib15] Furthermore, a pharmacophore-based virtual screening approach of commercial databases identified several micromolar ACE2 inhibitors. The best inhibitor was 4S-16659 (IC~50~  = 62,000 nM).[@bib16] Finally, researchers at the University of Florida also utilized a virtual screening exercise of the NCI database to identify *N*-(2-aminoethyl)-1 aziridine-ethanamine (NAAE) (IC~50~  = 57,000 nM) as an irreversible inhibitor of ACE2.[@bib17]

Recently, employing a directed screen of a set of metalloprotease inhibitors from the GlaxoSmithKline compound collection, GSK researchers reported the identification of a known ACE/NEP inhibitor as a potent inhibitor of the zinc metalloprotease ACE2.[@bib18] Structure/activity studies of the S^1^ subsite of ACE2 led to the identification of P^1^ modified thiol acid **1a** as a more potent ACE2 inhibitor (*K* ~i\ App~  = 1.5 nM) with improved selectivity versus ACE (*K* ~i\ App~  = 490 nM) and NEP (*K* ~i\ App~  = 27 nM). It also inhibits the M14 metalloprotease carboxypeptidase A1 (CpA, EC 3.4.17.1, *K* ~i\ App~  = 11,000 nM). Speculating that selectivity could be improved by exploiting potential differences in the S^1′^ subsites of ACE, ACE2, and NEP, the structure--activity relationships of the P^1′^ position of inhibitor **1a** were explored, with the goal of maintaining potency and reducing ACE and NEP inhibitory activity.

The thiol analogs **1a**--**1t** were prepared as depicted in [Scheme 1](#fig3){ref-type="fig"} . The amine hydrochlorides **2a**--**2t** were coupled to the acid **3**, after its in situ activation to the aza-hydroxybenzotriazole ester via the carbodiimide, to produce the fully protected amides. Then, hydrolysis of the thioacetate and methyl ester with lithium hydroxide afforded the thiol acids **1a**--**1t**.[@bib19] Scheme 1Reagents and conditions: (a) EDC, HOAt, *i*-Pr~2~NEt, CH~2~Cl~2~, rt, 39--76%; (b) LiOH·H~2~O, THF, H~2~O, rt, 56--94%.

Amine hydrochlorides **2a**--**2g**, **2l**, and **2o** were commercially available. The remaining amine hydrochlorides **2h**--**2k**, **2m**--**2n**, and **2p**--**2t** were prepared as depicted in [Scheme 2](#fig4){ref-type="fig"} . The commercially available amino acids **4a**--**4b** were converted to their corresponding methyl esters with thionyl chloride and methanol at reflux. Then, the resulting amine hydrochlorides were protected as the *tert*-butyl carbamates **5a**--**5b** with di-*tert*-butyl dicarbonate. A Suzuki cross coupling of the *o*-bromide **5a** (X = Br) with phenyl boronic acid afforded the *o*-biphenyl derivative **6a**. Acid catalyzed cleavage of the carbamate gave the *o*-biphenyl amine hydrochloride **2h**. The *m*-phenol **5b** (X = OH) was converted into the triflate with trifluoromethanesulfonic anhydride, and then coupled via the Suzuki protocol to phenyl boronic acid, providing the fully protected *m*-biphenyl derivative **6b**. Subsequent hydrolysis of the amine masking group gave the *m*-biphenyl amine hydrochloride **2i**. The *o*-bromide **5a** (X = Br) was converted into the *o*-phenol **5c** (X = OH) via palladium-mediated transformation of the bromide into a boronate ester, and then oxidation of the boronate to the phenol with hydrogen peroxide. Employing a modified Ullmann ether synthesis protocol, the *o*-phenol **5c** and *m*-phenol **5b** were coupled with phenyl boronic acid to afford the *o*- and *m*-diaryl ethers **6c** and **6d**. Acidic uncloaking of the *tert*-butyl carbonyl protecting group, then produced the phenyl ethers **2j** and **2k**. Finally, utilizing the Williamson ether synthesis, the *o*-phenol **5c**, the *m*-phenol **5b**, and the commercially available *p*-phenol **5d** were alkylated with various benzyl bromides to give the fully masked benzyl aryl ethers **6e**--**6k**. Then, unmasking of the carbamates afforded the amine hydrochlorides **2m**--**2n** and **2p**--**2t**.Scheme 2Reagents and conditions: (a) SOCl~2~, MeOH, ↑↓, 95--99%; (b) Boc~2~O, *i*-Pr~2~NEt, CH~2~Cl~2~, 0 °C to rt, 97--99%; (c) X = Br or OTf, PhB(OH)~2~, Pd(PPh~3~)~4~, K~2~CO~3~, PhMe, 90 °C, 41--57%; (d) X = OH, Tf~2~O, pyridine, CH~2~Cl~2~, 0 °C to rt, 88%; (e) X = Br, PdCl~2~(dppf), bis(pinacolato)diborane, KOAc, DMF, 80 °C; 30% H~2~O~2~ (aq), MeOH, 44%; (f) X = OH, Cu(OAc)~2~, PhB(OH)~2~, pyridine, powdered 4 Å molecular sieves, CH~2~Cl~2~, rt, 70--96%; (g) X = OH, ArCH~2~Br, K~2~CO~3~, acetone, rt, 71--99%; (h) HCl, MeOH, 91--98%.

The structure/activity relationships of P^1′^ analogs are depicted in [Table 1](#tbl1){ref-type="table"} . Complete removal of the P^1′^ substituent as in analog **1b** resulted in a large decrease in ACE2 (*K* ~i\ App~  = 90 nM) and NEP (*K* ~i\ App~  = 5100 nM) inhibitory activity. The potential reduction in van der Waals interactions from the absence of a P^1′^ side chain as well as the entropic gain from increased rotational freedom of the acid could account for this decrease in potency. In contrast, this change had little affect on ACE (*K* ~i\ App~  = 250 nM) or CpA (*K* ~i\ App~  = 35,000 nM). The alanine-derived analog **1c** (ACE2 *K* ~i\ App~  = 14 nM, NEP *K* ~i\ App~  = 950 nM) decreases rotational freedom and recovers some of the ACE2 inhibitory activity lost upon removal of the P^1′^ group, while not dramatically changing the activity versus ACE (*K* ~i\ App~  = 180 nM) or CpA (*K* ~i\ App~  = 11,000 nM). The phenylalanine and tyrosine derivatives **1d** (*K* ~i\ App~  = 1.5 nM) and **1e** (*K* ~i\ App~  = 1.3 nM) were equipotent ACE2 inhibitors to the methylene *p*-biphenyl analog **1a** with similar ACE (**1d** *K* ~i\ App~  = 570 nM, **1e** *K* ~i\ App~  = 410 nM) and NEP (**1d** *K* ~i\ App~  = 35 nM, **1e** *K* ~i\ App~  = 75 nM) activities as well. In contrast to **1a**, the benzyl derivatives **1d** and **1e** were \>10-fold more potent inhibitors of CpA (**1d** *K* ~i\ App~  = 530 nM, **1e** *K* ~i\ App~  = 350 nM). Since many good CpA substrates contain P^1′^ phenylalanine residues, this increase in CpA inhibition for **1d** and **1e** is not surprising.Table 1Inhibition of human ACE2, ACE, NEP, and CpA\#RACE2ACENEPCpA*K*~i\ App~[a](#tblfn1){ref-type="table-fn"} (nM)*K*~i\ App~[b](#tblfn2){ref-type="table-fn"} (nM)*K*~i\ App~[c](#tblfn3){ref-type="table-fn"} (nM)*K*~i\ App~[d](#tblfn4){ref-type="table-fn"} (nM)**1a**![](fx5.gif)1.54902711,000**1b**H90250510035,000**1c**Me1418095011,000**1d**![](fx6.gif)1.557035530**1e**![](fx7.gif)1.341075350**1f**![](fx8.gif)2.21800123600**1g**![](fx9.gif)2.4310467200**1h**![](fx10.gif)3720,0001909900**1i**![](fx11.gif)2.21000195000**1j**![](fx12.gif)0.9050001802300**1k**![](fx13.gif)5.811007914,000**1l**![](fx14.gif)2.2250108900**1m**![](fx15.gif)6.07701201600**1n**![](fx16.gif)2.4750375000**1o**![](fx17.gif)2.75703004600**1p**![](fx18.gif)2.5400018016,000**1q**![](fx19.gif)2.0950751900**1r**![](fx20.gif)0.8518006403300**1s**![](fx21.gif)35260015004600**1t**![](fx22.gif)8425,00011,00011,000[^1][^2][^3][^4]

It was decided to explore other bulky P^1′^ substituents with the goal of further improving on the potency and/or selectivity of analog **1a**, since the bulky methylene biphenyl P^1′^ moiety is readily accommodated by the ACE2 enzyme, implying a large S^1′^ subsite. Although the α-methylene naphthyl and the β-methylene naphthyl derivatives **1f** (*K* ~i\ App~  = 2.2 nM) and **1g** (*K* ~i\ App~  = 2.4 nM) were also potent ACE2 inhibitors with \>100-fold selectivity versus ACE (**1f** *K* ~i\ App~  = 1,800 nM, **1g** *K* ~i\ App~  = 310 nM) and CpA (**1f** *K* ~i\ App~  = 3600 nM, **1g** *K* ~i\ App~  = 7200 nM), they still retained substantial inhibitory activity against NEP (**1f** *K* ~i\ App~  = 12 nM, **1g** *K* ~i\ App~  = 46 nM).

In contrast to the *p*-phenyl phenylalanine derivative **1a**, the *o*-phenyl phenylalanine analog **1h** (*K* ~i\ App~  = 37 nM) was an order of magnitude less potent ACE2 inhibitor. This substitution also reduced ACE (*K* ~i\ App~  = 20,000 nM) and NEP (*K* ~i\ App~  = 190 nM) inhibition, while not altering CpA potency (*K* ~i\ App~  = 9900 nM). In contrast to **1h**, the methylene *m*-biphenyl derivative **1i** (*K* ~i\ App~  = 2.2 nM) was an equipotent ACE2 inhibitor to the *p*-derivative **1a**, despite branching from the phenyl moiety at a different angle, but it offered no clear selectivity advantages over ACE (*K* ~i\ App~  = 1000 nM), NEP (*K* ~i\ App~  = 19 nM), or CpA (*K* ~i\ App~  = 5000 nM) versus **1a**.

Although the large biphenyl derivatives were fairly rigid, they were tolerated in the S^1′^ subsite of ACE2. Thus, bulkier P^1′^ groups were explored. The *o*-, *m*-, and *p*-phenoxy phenylalanine derivatives **1j** (*K* ~i\ App~  = 0.90 nM), **1k** (*K* ~i\ App~  = 5.8 nM), and **1l** (*K* ~i\ App~  = 2.2 nM) retained good potency for ACE2 inhibition and \>100-fold selectivity versus ACE (**1j** *K* ~i\ App~  = 5000 nM, **1k** *K* ~i\ App~  = 1100 nM, **1l** *K* ~i\ App~  = 250 nM) and CpA (**1j** *K* ~i\ App~  = 2300 nM, **1k** *K* ~i\ App~  = 14,000 nM, **1l** *K* ~i\ App~  = 8900 nM), despite altered branching termini. In contrast, their NEP selectivity differed. The *o*-phenyloxy analog **1j** (*K* ~i\ App~  = 180 nM) was 200-fold selective versus NEP, while the *m*-phenoxy analog **1k** (*K* ~i\ App~  = 79 nM) and the *p*-phenoxy analog **1l** (*K* ~i\ App~  = 10 nM) were 14-fold and 5-fold NEP selective, respectively.

Surprisingly, the extended *o*-, *m*-, and *p*-benzyloxy phenylalanine derivatives **1m** (*K* ~i\ App~  = 6.0 nM), **1n** (*K* ~i\ App~  = 2.4 nM), and **1o** (*K* ~i\ App~  = 2.7 nM) were also well tolerated in the S^1′^ subsite of ACE2. In addition, they maintained good selectivity versus ACE (**1m** *K* ~i\ App~  = 770 nM, **1n** *K* ~i\ App~  = 750 nM, **1o** *K* ~i\ App~  = 570 nM) and CpA (**1m** *K* ~i\ App~  = 1600 nM, **1n** *K* ~i\ App~  = 5000 nM, **1o** *K* ~i\ App~  = 4600 nM). In contrast to the phenyloxy analogs, the *p*-benzyl analog **1o** (*K* ~i\ App~  = 300 nM) was quite selective versus NEP (110-fold), while the *o*-benzyloxy analog **1m** (*K* ~i\ App~  = 120 nM) and the *m*-benzyloxy analog **1n** (*K* ~i\ App~  = 37 nM) were less selective (20-fold and 15-fold, respectively).

Both the methylene *o*-phenoxyphenyl derivative **1j** and the methylene *p*-benzyloxyphenyl analog **1o** are potent and selective ACE2 inhibitors, but the latter inhibitor is readily derived from the cheap natural amino acid tyrosine. Therefore, fluorinated derivatives of inhibitor **1o** were prepared with the goal of maintaining potency and selectivity, while blocking potential metabolic sites of the naked phenyl ring. It was hoped that electron withdrawing groups would not only sterically impede metabolism, but also electronically deactivate the aryl ring to oxidation. The mono- and difluoro analogs **1p** (*K* ~i\ App~  = 2.5 nM), **1q** (*K* ~i\ App~  = 2.0 nM), and **1r** (*K* ~i\ App~  = 0.85 nM) were potent ACE2 inhibitors with good selectivity. The 3,4-difluorobenzyl tyrosine derivative **1r** was the most selective analog with \>750-fold separation in *K* ~i\ App~s between ACE2 and ACE (*K* ~i\ App~  = 1800 nM), NEP (*K* ~i\ App~  = 640 nM), and CpA (*K* ~i\ App~  = 3300 nM). In contrast to the ACE2 inhibition of the fluoro derivatives **1p**--**1r**, the larger trifluoromethyl derivatives **1s** (*K* ~i\ App~  = 35 nM) and **1t** (*K* ~i\ App~  = 84 nM) were substantially less potent ACE2 inhibitors. Likely, these larger P^1′^ substituents clash with the residues that make up the S^1′^ subsite.

In vitro drug metabolism and pharmacokinetic assays were performed to help predict *in vivo* oral bioavailabilities and pharmacokinetics of the thiols. Although these inhibitors conform to Lipinski's Rule of 5, the Madin-Darby canine kidney (MDCK) assay revealed that this inhibitor class had poor to moderate passive cell permeabilities (P~APP~  = 5--47 nm/s).[@bib20] Since many dipeptides are absorbed by active transport mechanisms, representative thiol-based inhibitors were dosed orally in the rat despite their poor predicted cell permeation, but they had limited absorption (*F*  \< 10%) in agreement with the MDCK assay.

A model[@bib21], [@bib22] of the thiol **1r** docked into the active site of ACE2 based on the recent Millennium X-ray crystal structure[@bib23] is shown in [Figure 1](#fig1){ref-type="fig"} . It provides insight into the P^1′^ SAR of the thiol series. The terminal carboxylate of the inhibitor accepts hydrogen bonds from the imidazoles of ^345^His and ^505^His and forms a salt bridge to the guanidine of ^273^Arg. Also, the amide nitrogen of the inhibitor donates a hydrogen atom to the carbonyl of ^346^Pro, while the amide carbonyl accepts a hydrogen atom from ^515^Tyr. Moreover, in addition to its normal ACE2 ligands, the imidazole nitrogens of ^374^His and ^378^His and the carboxylate of ^402^Glu, the active site zinc coordinates the thiol of the inhibitor. Furthermore, the P^1^ *sec*-butyl group of the inhibitor forms van der Waals interactions with the S^1^ pocket composed of ^347^Thr, ^504^Phe, ^510^Tyr, and ^514^Arg. The greasy P^1′^ 3,4-difluorobenzyltyrosine side chain of **1r** forms significant lipophilic interactions with the quite large S^1′^ channel composed of the lengthwise canal between the two subdomains, including residues ^274^Phe, ^445^Thr, ^406^Glu, ^409^Ser, ^370^Leu, ^371^Thr, ^276^Thr and extending over to ^441^Lys and ^442^Gln. Although several residues in this pocket are hydrophilic, most of the polar groups are either involved in hydrogen bonds with other enzyme residues or oriented away from the S^1′^ pocket, maintaining the lipophilic nature of this subsite. Based on this model, the 3,4-difluorobenzyl portion of the P^1′^ substituent is hypothesized to occupy a different part of this large pocket than the P^1′^ side chain of the carboxyl inhibitor MLN-4760 co-crystallized in 1R4L.Figure 1A model of the thiol compound **1r** bound to the active site of ACE2 based on the X-ray co-crystal structure of MLN-4760 bound to ACE2 (PDB code 1R4L). The ACE2 carbons are colored cyan with inhibitor **1r** carbons colored green. The semi-transparent gray surface represents the molecular surface, while hydrogen bonds are depicted as yellow dashed lines. Several residues were removed for visual clarity. This figure was generated using PYMOL version 1.0 (Delano Scientific, [www.pymol.org](http://www.pymol.org)).

In contrast, as shown in [Figure 2](#fig2){ref-type="fig"} , a model[@bib21], [@bib22] of the thiol **1j** docked into the active site of ACE2 revealed that the *o*-phenyloxy P^1′^ group occupies a different part of the S^1′^ subsite than the 3,4-difluorobenzyl substituent of analog **1r**. The *o*-phenyloxy P^1′^ moiety fits into a portion of the S^1′^ subsite composed of ^360^Met, ^346^Pro, ^362^Thr, ^271^Trp, ^368^Asp, ^371^Thr, ^127^Tyr, ^144^Leu, ^149^Asn, ^363^Lys, and ^269^Asp, and the disulfide pair of ^344^Cys and ^361^Cys. Thus, the *o*-phenyloxy P^1′^ moiety of **1j** binds similarly to the P^1′^ side chain of the Millennium carboxyl inhibitor MLN-4760 co-crystallized in 1R4L. The other interactions of inhibitor **1j** are similar to those for analog **1r**. Thus, these two models help explain the divergent P^1′^ SAR, since the very large, forked S^1′^ subsite can tolerate substituents with different branching points.Figure 2A comparison of the models of the thiol compounds **1j** (carbons colored in green) and **1r** (carbons colored in magenta) bound to the active site of ACE2 (carbons colored in cyan) based on the X-ray co-crystal structure (PDB code 1R4L). The semi-transparent gray surface represents the molecular surface, while hydrogen bonds are depicted as yellow dashed lines. Several residues were removed for visual clarity. This figure was generated using PYMOL version 1.00.

In summary, variation of substituents at the P^1′^ position in a series of α-thiol amide-based inhibitors of ACE2 resulted in the discovery of potent inhibitors with good ACE and NEP selectivity. Inhibitors containing *p*-methylene aryl tyrosine P^1′^ moieties like **1o**, **1p**, and **1r** were some of the more selective ACE2 inhibitors. In addition, *o*-phenyloxy phenylalanine analog **1j** was also a potent and selective ACE2 inhibitor. These analogs may prove useful in further defining the roles ACE2 plays in the RAS cascade.
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[^1]: Inhibition of recombinant human ACE2 activity in a fluorescence assay using 0.4 nM ACE2, 30 μM MCA-Tyr-Val-Ala-Asp-Ala-Pro-Lys(DNP)-OH as substrate in 1 μM Zn(OAc)~2~, 100 μM TCEP, 50 mM Hepes, 300 μM CHAPS, and 300 mM NaCl at pH = 7.5. The *K*~i\ App~ values are means of at least two inhibition assays.

[^2]: Inhibition of recombinant human ACE activity in a fluorescence assay using 0.5 nM ACE, 10 μM MCA-Ala-Ser-Asp-Lys-Dap(DNP)-OH as substrate in 1 μM Zn(OAc)~2~, 100 μM TCEP, 50 mM Hepes, 300 μM CHAPS, and 300 mM NaCl at pH = 7.5. The *K*~i\ App~ values are means of at least two inhibition assays.

[^3]: Inhibition of recombinant human NEP activity in a fluorescence assay using 0.15 nM NEP, 2 μM FAM-Gly-Pro-Leu-Gly-Leu-Phe-Ala-Arg-Lys(TAMRA)-NH~2~ as substrate in 1 μM Zn(OAc)~2~, 100 μM TCEP, 50 mM Hepes, 300 μM CHAPS, and 300 mM NaCl at pH = 7.5. The *K*~i\ App~ values are means of at least two inhibition assays.

[^4]: Inhibition of recombinant human CpA activity in a fluorescence assay using 37 nM CpA, 30 μM Abz-Gly-Gly-Nph-OH as substrate in 1 μM Zn(OAc)~2~, 100 μM TCEP, 50 mM Hepes, 300 μM CHAPS, and 300 mM NaCl at pH = 7.5. The *K*~i\ App~ values are means of at least two inhibition assays.
